Table 1.
Descriptive Statistics of Switch and Control Groups
| Switch (N = 195) |
Control (N = 237) |
P-value | Totala (N = 432) |
|
|---|---|---|---|---|
| Age at baseline (years) | 33 (23–50) | 44 (30–58) | <.001 | 39 (27–54) |
| Sex | .61 | |||
| Men | 102 (52.3%) | 117 (49.4%) | 219 (50.7%) | |
| Women | 93 (47.7%) | 120 (50.6%) | 213 (49.3%) | |
| Diagnosesb | <.001 | |||
| Psychotic disorders | 101 (51.8%) | 64 (27.0%) | 165 (38.2%) | |
| Depression | 29 (14.9%) | 42 (17.7%) | 71 (16.4%) | |
| Bipolar disorder | 20 (10.3%) | 45 (19.0%) | 65 (15.0%) | |
| Schizoaffective disorders | 26 (13.3%) | 13 (5.5%) | 39 (9.0%) | |
| Others | 10 (5.1%) | 23 (9.7%) | 33 (7.6%) | |
| Missing | 9 (4.6%) | 50 (21.1%) | 59 (13.7%) | |
| Duration of 1st follow-upc (days) | 92 (45–170) | 380 (360–430) | <.001 | 350 (100–390) |
| Duration of 2nd follow-upc (days) | 140 (61–340) | 380 (360–430) | <.001 | 360 (170–390) |
| Total follow-up durationd (days) | 290 (160–520) | 380 (360–430) | <.001 | 370 (290–460) |
| BMI at baselinee (Kg/m2) | 23 (21–26) | 24 (21–27) | .43 | 23 (21–26) |
| Missing | 3 (1.5%) | 21 (8.9%) | 24 (5.6%) | |
| BMI between follow-upse (kg/m2) | 24 (22–28) | 24 (21–27) | .10 | 24 (21–27) |
| Missing | 3 (1.5%) | 21 (8.9%) | 24 (5.6%) | |
| Smoking | .81 | |||
| Yes | 95 (48.7%) | 95 (40.1%) | 190 (44.0%) | |
| No | 89 (45.6%) | 83 (35.0%) | 172 (39.8%) | |
| Missing | 11 (5.6%) | 59 (24.9%) | 70 (16.2%) | |
| Psychotropic co-medicationf | .060 | |||
| Yes | 50 (25.6%) | 42 (17.7%) | 92 (21.3%) | |
| No | 145 (74.4%) | 195 (82.3%) | 340 (78.7%) | |
| Medical environment | <.001 | |||
| Inpatients | 134 (68.7%) | 30 (12.7%) | 164 (38.0%) | |
| Outpatients | 61 (31.3%) | 207 (87.3%) | 268 (62.0%) |
Note: BMI, body mass index.
Note: Information follows.
aMedian with quartiles 1 - 3 and proportions are reported for continuous and categorical variables, respectively.
bInternational Classification of Diseases-10th Revision classification: organic disorders, anxiety, personality disorder, intellectual disability, dementia, and substance use disorder were classified together as “other.”
cFirst (before switch) and second (after switch) follow-up duration is the same for controls.
dFor the switch group, it refers to the sum of the 2 follow-ups durations (ie, first and second).
eControls have the same BMI at baseline and between follow-ups. For the switch group, BMI at baseline refers to the BMI at the beginning of the 1st follow-up, and BMI between follow-ups refers to the BMI at the moment of the switch.
fPsychotropic comedication with potential for increasing weight: haloperidol, pipamperone, flupentixol, asenapine, amisulpride, aripiprazole, lurasidone, zuclopenthixol, levomepromazine, risperidone/paliperidone, quetiapine, lithium, mirtazapine, valproate, olanzapine, and clozapine.
Note: Significant P-values are in bold.